LUMENIX is covered by the following patents and applications: Australia (2010313785), Austria (2493457), Belgium (2493457), Canada (2,777,218), China (ZL201080046185.X), Denmark (2493457), Finland (2493457), France (2493457), Germany (2493457), Hong Kong (HK1175690), India (1323/MUMNP/2012), Indonesia (IDP000036973), Ireland (2493457), Italy (502017000115917), Japan (5777170), Macau (J/3050), Malaysia (MY-150626-A), Netherlands (2493457), New Zealand (599594), Norway (2493457), Poland (2493457), South Korea (10-1612073), Singapore (174465), Spain (2493457), Sweden (2493457), Switzerland (2493457), Thailand (1201001664), Turkey (2493457), United Kingdom (2493457), USA (13/504,309), Vietnam (21037).
Medical records analysis showed that about 1.5 percent of non-diabetic men taking semaglutide had erectile dysfunction (ED)more than men who didnt take the weight-loss drug
L-Glutathione is an important water-soluble antioxidant that helps fight free radical oxidative stress.*
These findings suggest that Se may modulate the pathogenesis of AD by inhibiting A aggregation and Tau protein phosphorylation, potentially altering the disease course
